Drug

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

5 days ago   |   By Xconomy

Two weeks after MorphoSys filed for FDA review of its experimental treatment for a form of lymphoma, the company has struck a deal with Incyte to further develop and commercialize the therapy in the US and around the world. According to financial terms announced Monday, Incyte is paying MorphoySys $750 million up front for the right to co-commercialize the drug tafasitamab in the US, where profits will be split equally. In addition, Wilmington, DE-based Incyte will buy $150 million worth of MorphoSys stock at an unspecified premium. The deal also gives Incyte the right to...
Read more ...

 


Search by Tags

   Drug      Drugs      Therapies      Europe blog main      Europe top stories      National      National blog main      National top stories      Bendamustine      Biotech      CAR-T      Chemotherapy      Chronic Lymphocytic Leukemia      Clinical trials      Diffuse Large B-Cell Lymphoma      FDA      Follicular lymphoma      Geoffrey Porges      Immunotherapy      Incyte      Lenalidomide      Life Sciences      Lymphoma      Lymphoma Research Foundation      Marginal zone lymphoma      MorphoSys      Parsaclisib      Rituximab      SVB Leerink      Tafasitanib  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they're “undruggable.”... Read more ...

AveXis Inc.: Research Associate III

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Student Assistant

Mirati Therapeutics: Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations San... Read more ...

Inhibition of lignification of Zizania latifolia with radio frequency...

Zizania latifolia is easily lignified after harvesting, leading to the degradation of food quality and commercial value. Thus, this study evaluated the effect of radio... Read more ...

Performance difference of graph-based and alignment-based hybrid error...

The error-prone third-generation sequencing long reads can be corrected by the high-quality second-generation sequencing short reads, which is referred to as hybrid error... Read more ...

CHROMATIX: computing the functional landscape of many-body chromatin...

Chromatin interactions are important for gene regulation and cellular specialization. Emerging evidence suggests many-body spatial interactions play important roles in... Read more ...

Bachem: Validation Engineer II, QA

Bachem: Your Responsibilities The Validation Engineer II fulfills a critical role in GMP operations. This individual must plan and execute validation studies, Vista, CA, US ... Read more ...

AveXis Inc.: Senior Scientist, Molecular Biology

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Talent Partner

Mirati Therapeutics: Reporting to the Head of Business, Culture and Talent this role will be partner with C-Level executive(s) and their staff. This role will be responsib San... Read more ...

Selective inhibition of matrix metalloproteinase 10 with a single-domain...

Since their discovery, the matrix metalloproteinase family of proteases have been considered as therapeutic targets in numerous diseases and disorders. Unfortunately, clinical... Read more ...